{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:54:31Z","timestamp":1761630871558,"version":"3.41.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biologic medications have advanced the management of inflammatory bowel diseases (IBD) but are underutilized in the treatment algorithm. One reason may be related to patients\u2019 concerns about adverse events and their perceptions of risk. The aim of this study was to compare patients\u2019 perceptions of risk of IBD treatment with their perceived risk of everyday occurrences and other medications and how these perceptions may be influenced by personality traits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional study of consecutive IBD patients was conducted at a single tertiary care center. Participants were asked to report about their perception of risk of IBD medications, non-IBD medications, invasive procedures, and everyday life occurrences. Participants responded also to the Multidimensional Health Locus of Control (MHLC) scale to characterize beliefs about control over health outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 130 patients with IBD completed the questionnaires. There was a broad range of disease severity and prior medication use. Biologics elicited the highest dread of all IBD medications, but this was still lower than their fear of surgery. Patients believed that biologics were of higher benefit than immunomodulators and mesalamines, but riskier. Having the personality trait of an internally developed locus of control was associated with the perception that biologics are less dreadful.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients with IBD perceive biologics to be of higher benefit but riskier and more dreadful as compared with immunomodulators. Risk perception may be about more than their knowledge base but also about how much control patients typically believe they have over their daily lives.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izz121","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T02:25:50Z","timestamp":1562984750000},"source":"Crossref","is-referenced-by-count":4,"title":["Patients\u2019 Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications"],"prefix":"10.1093","author":[{"given":"Jenna L","family":"Koliani-Pace","sequence":"first","affiliation":[{"name":"Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M","family":"Haron","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaara","family":"Zisman-Ilani","sequence":"additional","affiliation":[{"name":"College of Public Health, Temple University, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly D","family":"Thompson","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey A","family":"Siegel","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,7,13]]},"reference":[{"key":"2019071222254937800_CIT0001","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2019071222254937800_CIT0002","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1097\/MIB.0b013e3182807618","article-title":"Do inflammatory bowel disease therapies cause cancer?","volume":"19","author":"Mason","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2019071222254937800_CIT0003","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/gutjnl-2011-300988","article-title":"Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options","volume":"61","author":"Siegel","year":"2012","journal-title":"Gut."},{"key":"2019071222254937800_CIT0004","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/ibd.21305","article-title":"Lost in translation: helping patients understand the risks of inflammatory bowel disease therapy","volume":"16","author":"Siegel","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2019071222254937800_CIT0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2010.04489.x","article-title":"Review article: explaining risks of inflammatory bowel disease therapy to patients","volume":"33","author":"Siegel","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2019071222254937800_CIT0006","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000203638","article-title":"Patient\u2019s perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease","volume":"79","author":"Baars","year":"2009","journal-title":"Digestion."},{"key":"2019071222254937800_CIT0007","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2007.04.075","article-title":"Crohn\u2019s disease patients\u2019 risk-benefit preferences: serious adverse event risks vs treatment efficacy","volume":"133","author":"Johnson","year":"2007","journal-title":"Gastroenterology."},{"key":"2019071222254937800_CIT0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.20283","article-title":"Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease","volume":"14","author":"Siegel","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"2019071222254937800_CIT0009","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1126\/science.3563507","article-title":"Perception of risk","volume":"236","author":"Slovic","year":"1987","journal-title":"Science."},{"key":"2019071222254937800_CIT0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/109019817800600107","article-title":"Development of the Multidimensional Health Locus of Control (MHLC) scales","volume":"6","author":"Wallston","year":"1978","journal-title":"Health Educ Monogr."},{"key":"2019071222254937800_CIT0011","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1207\/s15327752jpa6303_10","article-title":"Form C of the MHLC scales: a condition-specific measure of locus of control","volume":"63","author":"Wallston","year":"1994","journal-title":"J Pers Assess."},{"key":"2019071222254937800_CIT0012","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/ajg.2009.197","article-title":"The manitoba IBD index: evidence for a new and simple indicator of IBD activity","volume":"104","author":"Clara","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"2019071222254937800_CIT0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/009286150704100110","article-title":"Risk perception of prescription drugs: results of a national survey","volume":"41","author":"Slovic","year":"2007","journal-title":"Drug Inf J."},{"key":"2019071222254937800_CIT0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-0771(200001\/03)13:1<1::AID-BDM333>3.0.CO;2-S","article-title":"The affect heuristic in judgments of risks and benefits","volume":"13","author":"Finucane","year":"2000","journal-title":"J Behav Decis Mak."},{"volume-title":"Slovic, P, Finucane ML, Peters E, MacGregor DG. Risk as Analysis and Risk as Feelings: Some Thoughts about Affect, Reason, Risk, and Rationality. Risk Anal. 2004;24:311\u2013322.","key":"2019071222254937800_CIT0015"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izz121\/28932619\/izz121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T02:25:57Z","timestamp":1562984757000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article\/doi\/10.1093\/ibd\/izz121\/5531845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,13]]},"references-count":15,"URL":"https:\/\/doi.org\/10.1093\/ibd\/izz121","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published":{"date-parts":[[2019,7,13]]},"article-number":"izz121"}}